Vir reported Q4 2025 revenue of USD 64.1 million and a net loss attributable to shareholders of USD 42.9 million (USD 0.31 per share). R&D expenses were USD 88.3 million and SG&A expenses were USD 23.6 million. Cash, cash equivalents and investments totaled USD 781.6 million as of December 31, 2025. For FY 2025, Vir posted revenue of USD 68.6 million and a net loss attributable to shareholders of USD 438 million (USD 3.16 per share), with R&D expenses of USD 456 million and SG&A expenses of USD 92.1 million. During the period, Vir announced a global strategic collaboration with Astellas to advance PSMA-targeted dual-masked T-cell engager VIR-5500 in metastatic castration-resistant prostate cancer, and reported updated Phase 1 dose-escalation data supporting dose-dependent anti-tumor activity and a well-tolerated safety profile. Vir said monotherapy and combination dose-expansion cohorts are expected to start in Q2 2026, followed by pivotal Phase 3 trials in 2027. In chronic hepatitis delta, Vir highlighted Phase 2 SOLSTICE Week 96 results showing HDV RNA target not detected in 88% of evaluable participants, and said ECLIPSE 1 topline data are expected in Q4 2026. Vir also cited a December 2025 licensing agreement with Norgine for tobevibart plus elebsiran in Europe, Australia and New Zealand, and noted a USD 64.3 million initial cost reimbursement payment received on signing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602231714BIZWIRE_USPR_____20260222_BW469334) on February 23, 2026, and is solely responsible for the information contained therein.